Publicaciones en colaboración con investigadores/as de Hospital General de Castellón (17)

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  2. No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

    Disease markers, Vol. 2022, pp. 3132941

  3. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

  3. Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

    Leukemia and Lymphoma, Vol. 62, Núm. 11, pp. 2727-2736

  4. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  5. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  6. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

    Transplantation and Cellular Therapy, Vol. 27, Núm. 4, pp. 311.e1-311.e10

  7. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry

    Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732

2014

  1. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

2013

  1. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

    Medical Mycology, Vol. 51, Núm. 2, pp. 150-154

2010

  1. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study

    European Journal of Haematology

  2. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci

    Genes Chromosomes and Cancer, Vol. 49, Núm. 8, pp. 726-732

2009

  1. Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 4, pp. 512-516

  2. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

    Multiple Sclerosis, Vol. 15, Núm. 11, pp. 1303-1310